Found 9 matching trials
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
PHASE3The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the ...
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
PHASE3The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the l...
Extension Study of PRX-102 for up to 60 Months
PHASE1To evaluate the ongoing safety, tolerability, and efficacy parameters of PR...
Location
University of Florida
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
PHASE3This was a randomized, double-blind, active control study of the enzyme rep...
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
PHASE2A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in ...
Location
Phoenix Children's
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
PHASE3The study will be a randomized, double blind, placebo-controlled study of t...
Location
Multiple Locations
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
PHASE3This is an open label switch over study to assess the safety and efficacy o...
Location
Royal Melbourne Hospital
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
PHASE2The aim of this study is to evaluate the safety and efficacy of pegunigalsi...
Location
Fukuoka University Chikushi Hospital
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
PHASE3This open-label switchover study will assess the safety, efficacy, and phar...